/
MSH6 Gene Curation

MSH6 Gene Curation

Gene-disease assertions not curated here (add link or write note): hereditary breast carcinoma (disputed by hereditary cancer GCEP).

Disease

Lynch syndrome

Disease

Lynch syndrome

Inheritance

Autosomal dominant

Prevalence

 1:279

Source: 20301390

 

Rapid or full curation?

Rapid
Full

ClinGen / GenCC / BabySeq / HGMD

ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Clinical Validity Scoring Notes and points

MSH6 was first reported in relation to autosomal dominant Lynch Syndrome (LS, MONDO:0005835) in 1997 (Miyaki M. et al., PMID: 9354786). Lynch syndrome (LS), previously known as hereditary nonpolyposis colorectal cancer (HNPCC), is a cancer predisposition syndrome; LS is caused by pathogenic germline variants (PGV) in DNA mismatch repair (MMR) genes, including MSH6, inherited in an autosomal dominant pattern. Biallelic MSH6 PGVs also cause a distinct mismatch repair deficiency cancer syndrome. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we separate these two curations due to different inheritance patterns and phenotype. This curation only focuses on the dominant LS condition. In this curation, we included 14 PGVs, including missense, deletions, nonsense, and duplications that have been reported in multiple patients and families (PMIDs: 9354786, 10521294, 36612224, 11709755, 26805314). More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism of pathogenicity appears to be loss of function (LOF). MSH6-Lynch Syndrome association is supported by experimental evidence at a biochemical and functional level (6 points). Drummond JT et al., 1995, (PMID: 7604264) describes the isolation of an MSH2–MSH6 heterodimer that restores DNA mismatch repair to tumor cells; in the same issue, Palombo F, et al., 1995, (PMID: 7604265) reported that the DNA mismatch recognition and binding in human cells has been thought to be mediated by the hMSH2 protein, they showed that the mismatch-binding factor consists of two distinct proteins, the 100-kilodalton hMSH2 and a 160-kilodalton polypeptide, GTBP (for G/T binding protein). Both proteins are required for mismatch-specific binding, a result consistent with the finding that tumor-derived cell lines devoid of either protein are also devoid of mismatch-binding activity. Sequence analysis identified GTBP as a new member of the MutS homolog family. Edelmann W, et al., (PMID: 9390556) also reported that extracts from the Msh6-/- cells were defective for the repair of single nucleotide mismatches. In addition, homozygous mice had a reduced lifespan and developed a spectrum of tumors. The mice showed tumors in the intestine (adenoma), the liver (hepatoma), and B- and T-cell lymphomas. In summary, MSH6 is definitively associated with autosomal dominant inheritance and Lynch Syndrome. This has been repeatedly demonstrated in research and clinical diagnostic settings and upheld over time. This gene-disease pair was initially evaluated by the Colon Cancer Expert Panel on 09/25/2017. It was reevaluated on 03/24/2023 (SOP Version 9). As a result of this reevaluation, the classification did not change.

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Clinical Validity Points Total

18

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Clinical Validity Classification

Definitive (12pts)

Strong (12pts)

Moderate (7-11pts)

Limited (0.1-6pts)

No genetic evidence

Refuted

Disputed

Definitive

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Molecular Mechanism

Loss of function

Gain of function

Dominant negative

Unknown

Other

Loss of function

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023. pLOF variants used in curation:

NM_000179.3(MSH6):c.3772C>T (p.Gln1258Ter) 10521294

NM_000179.3(MSH6):c.651dup (p.Lys218Ter) 10521294

NM_000179.3(MSH6):c.3838C>T (p.Gln1280Ter) 11709755

 

Penetrance

Complete (100%)

High (≥80%)

Moderate  (<80% and >20%)

Low (≤20%)

(list source/PMID)

Moderate (age-related)

Source: PMID: 20301390

Age of Onset

Congenital

Pediatric

Adolescent

Adulthood

Late adulthood

(list source/PMID)

Adulthood

Source: https://rarediseases.info.nih.gov/diseases/9905/lynch-syndrome

Severity

Moderate

Clinical Features

Increased risk for colorectal cancer and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate.

Sources: PMID: 20301390

HPO Terms

https://hpo.jax.org/app/

HP:0006716 Hereditary nonpolyposis colorectal carcinoma

HP:0010784 Uterine neoplasm

HP:0100615 Ovarian neoplasm

HP:0012126 Stomach cancer

HP:0100833 Neoplasm of the small intestine

HP:0010786Urinary tract neoplasm

HP:0100574Biliary tract neoplasm

HP:0012174Glioblastoma multiforme

HP:0009720Adenoma sebaceum

HP:0030410Sebaceous gland carcinoma

HP:0031525Keratoacanthoma

HP:0002894Neoplasm of the pancreas

HP:0012125Prostate cancer

Gene SOPs & Notes

None found

Curation Summary

The MSH6 gene is associated with autosomal dominant Lynch syndrome, which is characterized by an increased risk of colorectal cancer and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate (PMID: 20301390). The National Comprehensive Cancer Network describes guidelines for the surveillance and prevention strategies for individuals at risk for Lynch syndrome due to pathogenic MSH6 variants.

 

The MSH6 gene is also associated with autosomal recessive mismatch repair deficiency syndrome, which is characterized by colonic adenomas, cafe au lait macules, hematologic cancers, brain tumors, cavernous brain hemangiomas, agenesis of the corpus callosum, other malignancies and congenital malformations (PMID: 24737826).

Case ID, Curator name, Date, Jira ticket link

Andrea Oza 08.04.2023, https://broadinstitute.atlassian.net/browse/BCL-1

 

Disease

Mismatch repair cancer syndrome

aka Constitutional mismatch repair deficiency syndrome

Disease

Mismatch repair cancer syndrome

aka Constitutional mismatch repair deficiency syndrome

Inheritance

Autosomal recessive

Prevalence

 Unknown

Source: ORPHA:252202

Rapid or full curation?

Rapid
Full

ClinGen / GenCC / BabySeq / HGMD

ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Clinical Validity Scoring Notes and points

There has been sufficient evidence published associating the MSH6 gene with constitutional mismatch repair deficiency syndrome - a distinct disorder from Lynch syndrome - since the gene-disease relationship was first proposed by Menko, et al., (2004). Multiple case level studies have been performed with cMMRD patients that have variants in the MSH6 gene. Other mismatch repair (MMR) genes MLH1, MSH2 and PMS2 also causes constitutional mismatch repair deficiency syndrome. IHC and western blot revealed absence of MSH6 protein in patient cells. Multiple MSH6 deficient mouse and zebrafish models have been established to show consistent phenotypes with MMRCS patients by developing neurofibromas, non-Hodgkin’s lymphoma (NHL) and gastrointestinal (GI) tumors. All of these types of evidence are consistent with a definitive relationship between the MSH6 gene and constitutional mismatch repair deficiency syndrome.

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Clinical Validity Points Total

18

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Clinical Validity Classification

Definitive

Source: ClinGen Hereditary Cancer GCEP, accessed 08.04.2023

Molecular Mechanism

Loss of function

pLOF variants used in ClinGen Hereditary Cancer GCEP curation:

  1. NM_000179.3(MSH6):c.3633dup p.(Val1212Cysfs*3) PMID: 16000562

  2. NM_000179.2(MSH6):c.642C>G (p.Tyr214Ter) PMID: 17259933

  3. NM_000179.2(MSH6):c.1806_1809delAAAG p.(Glu604Leufs*5) PMID: 18409202

 

Penetrance

(list source/PMID)

Unknown

Source:

Age of Onset

(list source/PMID)

Pediatric

Severity

Severe

Clinical Features

Colonic adenomas, cafe au lait macules, hematologic cancers (Non-hodgkin’s lymphoma, lymphoid leukemia, AML), brain tumors (glioblastoma, medulloblastoma, supratentorial primitive neuroectodermal tumours ), cavernous brain hemangiomas, agenesis of the corpus callosum, other malignancies and congenital malformations.

Sources: PMID: 24737826

HPO Terms

https://hpo.jax.org/app/

Neoplasm of the colon HP:0100273

HP:0040276Adenocarcinoma of the colon

Non-Hodgkin lymphoma HP:0012539

HP:0002885Medulloblastoma

HP:0001010Hypopigmentation of the skin

HP:0012174Glioblastoma multiforme

HP:0001274Agenesis of corpus callosum

HP:0007565Multiple cafe-au-lait spots

HP:0004377Hematological neoplasm

Gene SOPs & Notes

 LINK if SOP is a long document. Short notes if it is easy to digest. eg. Last known truncating variant

Curation Summary

SEE ABOVE

Case ID, Curator name, Date, Jira ticket link

Andrea Oza 08.04.2023, https://broadinstitute.atlassian.net/browse/BCL-1